# Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT03333746** · PHASE2 · TERMINATED · sponsor: **Yvonne Efebera** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Nivolumab
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT03333746
- **Lead sponsor:** Yvonne Efebera
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-21
- **Primary completion:** 2018-08-13
- **Final completion:** 2018-11-16
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Study was discontinued due to FDA recommendations of the potential toxicities of the combination of drugs.
- **Last updated:** 2019-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03333746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03333746, "Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03333746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*